SCHEMBL10339603

SCHEMBL10339603

O=c1ccc(O)ccc1O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYR P14679 3/20 0.54
MMP2 P08253 1/20 0.52
DBH P09172 1/20 0.52
CA12 O43570 4/20 0.50
CA1 P00915 4/20 0.50
CA2 P00918 4/20 0.50
CA9 Q16790 4/20 0.50
CA14 Q9ULX7 4/20 0.50
MAPT P10636 3/20 0.50
CA3 P07451 3/20 0.50
ALOX15 P16050 3/20 0.50
KDM4E B2RXH2 2/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
LMNA P02545 2/20 0.50
HPGD P15428 2/20 0.50
CA4 P22748 2/20 0.50
CA5A P35218 2/20 0.50
CA5B Q9Y2D0 2/20 0.50
HSP90AA1 P07900 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14425214 0.77 TYR (0.50) TYRMMP2DBHCA1CA2
SCHEMBL916337 0.77 TYR (0.56) TYRMMP2DBHCA12CA1
SCHEMBL11193755 0.77 TYR (0.56) TYRMMP2DBHCA1CA2
SCHEMBL9865577 0.77 TYR (0.56) TYRMMP2DBHCA12CA1
SCHEMBL21465807 0.77 TYR (0.50) TYRMMP2DBHCA1CA2
SCHEMBL23250747 0.77 TYR (0.50) TYRMMP2DBHCA1CA2
SCHEMBL728289 0.73 MMP2 (0.64) TYRMMP2DBHMAPTALOX15
SCHEMBL916360 0.73 MAPK1 (0.59) TYRMMP2DBHMAPTKDM4E
SCHEMBL10668284 0.73 TSHR (0.60) TYRMMP2DBHCA12CA1
SCHEMBL17063224 0.71 LMNA (0.58) TYRMMP2DBHCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2237962-A None JP disclosed
JP-2237964-A None JP disclosed
CN-109562050-B Gel-like composition 株式会社钟化 2022-05-10 CN disclosed
EP-3533438-A1 GELATINOUS COMPOSITION Kaneka Corporation (JP) 2019-09-04 EP disclosed
US-20190247285-A1 GELATINOUS COMPOSITION KANEKA CORPORATION (JP) 2019-08-15 US disclosed
US-7259187-B2 Tropolone derivatives RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2007-08-21 US disclosed
US-7259187-B2 Tropolone derivatives RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2007-08-21 US disclosed
JP-H02237962-A TROPOLONE FLUOROBENZOIC ACID ESTER DERIVATIVE NIPPON SHOKUBAI KAGAKU KOGYO CO LTD 1990-09-20 JP disclosed
JP-H02237964-A TROPOLONE DERIVATIVE NIPPON SHOKUBAI KAGAKU KOGYO CO LTD 1990-09-20 JP disclosed
US-4883758-A Biologically pure culture of the microorganism Streptomycas tropolofaciens used for producing 3,7-dihydroxytropolone and antitumor use BRISTOL-MYERS COMPANY (US) 1989-11-28 US disclosed
US-4833079-A CULTURE OF STREPTOMYCES BRISTOL-MYERS COMPANY (US) 1989-05-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190247285-A1 GELATINOUS COMPOSITION DAGLA, GLA, DAGLB TYR 4599/4885MMP2 226/4885DBH 3649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.